1158680-88-6 = 79762-54-2 反应条件:1.1 Catalysts: Acetyl Chloride Solvents: Methanol; 2.5 H,Rt1.2 Reagents: Triethylamine; Rt 标题:Acetyl Chloride-Mediated Mild And Regioselective Attachment And Removal Of Tetrahydropyranyl (Thp) Group 作者:Suresh,Thatipally; Et Al 参考文献:International Journal Of Chemical Sciences 日期:2010 卷标:8(3) 页码:2013-2024]
39478-78-9 = 79762-54-2 反应条件:1.1 Reagents: Sodium Nitrite,Sodium Tetrafluoroborate1.2 Reagents: Potassium Acetate,18-Crown-6 Solvents: Chloroform 标题:3-(Indol-2-Yl)Indazoles As Chek1 Kinase Inhibitors: Optimization Of Potency And Selectivity Via Substitution At C6 作者:Fraley,Mark E.; Et Al 参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2006 卷标:16(23) 页码:6049-6053]
22532-62-3 = 79762-54-2 反应条件:1.1 Reagents: Hydrazine Hydrate (1:1) Catalysts: P-Toluenesulfonic Acid Solvents: Polyethylene Glycol; 1 - 4 H,80 - 90 °C 标题:Design,Synthesis And Evaluation Of Antibacterial Activity Of Novel Indazole Derivatives 作者:Chabukswar,Anuruddha; Et Al 参考文献:Current Bioactive Compounds 日期:2013 卷标:9(4) 页码:263-269]
57848-46-1 = 79762-54-2 反应条件:1.1 Reagents: Potassium Carbonate,O-Methylhydroxylamine Hydrochloride Solvents: 1,2-Dimethoxyethane; 40 °C1.2 Reagents: Hydrazine Solvents: 1,2-Dimethoxyethane; Reflux 标题:A Novel Series Of Indazole-/indole-Based Glucagon Receptor Antagonists 作者:Lin,Songnian; Et Al 参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2015 卷标:25(19) 页码:4143-4147]
651780-33-5 = 79762-54-2 反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Methanol,Water; 2 H,60 °C 标题:Discovery Of 5-Azaindazole (Gne-955) As A Potent Pan-Pim Inhibitor With Optimized Bioavailability 作者:Wang,Xiaojing; Et Al 参考文献:Journal Of Medicinal Chemistry 日期:2017 卷标:60(10) 页码:4458-4473]
14874-70-5 = 79762-54-2 反应条件:1.1 Reagents: Potassium Acetate,18-Crown-6 Solvents: Chloroform; 1 H,Rt 标题:4-Substituted Indazoles As New Inhibitors Of Neuronal Nitric Oxide Synthase 作者:Boulouard,Michel; Et Al 参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2007 卷标:17(11) 页码:3177-3180]
39478-78-9 = 79762-54-2 反应条件:1.1 Reagents: Potassium Acetate Solvents: Chloroform; 30 Min,Rt; 30 Min,60 - 65 °C1.2 Reagents: Isoamyl Nitrite; 30 Min; Overnight,Reflux2.1 Reagents: Hydrochloric Acid Solvents: Methanol,Water; 2 H,60 °C 标题:Discovery Of 5-Azaindazole (Gne-955) As A Potent Pan-Pim Inhibitor With Optimized Bioavailability 作者:Wang,Xiaojing; Et Al 参考文献:Journal Of Medicinal Chemistry 日期:2017 卷标:60(10) 页码:4458-4473
5-溴-2-氟苯甲醛置于hydrazine Hydrate体系中,用 二甲基亚砜 作为反应溶剂,化学反应 21.0H,以76%的收率获得产物6-溴吲唑 参考文献: Indazolyl,Benzimidazolyl,Benzotriazolyl Substituted Indolinone Derivatives As Kinase Inhibitors Useful In The Treatment Of Cancer[fr] Dérivés D'Indolmone à Substitution Indazolyle,Benzimidazolyle,Benzotriazolyle En Tant Qu'Inhibiteurs De Kinases Utilisés Dans Le Traitement Du Cancer 标题: Indazolyl,Benzimidazolyl,Benzotriazolyl Substituted Indolinone Derivatives As Kinase Inhibitors Useful In The Treatment Of Cancer[fr] Dérivés D'Indolmone à Substitution Indazolyle,Benzimidazolyle,Benzotriazolyle En Tant Qu'Inhibiteurs De Kinases Utilisés Dans Le Traitement Du Cancer
专利信息
专利号:US-10077255-B2 优先权日:2010-04-06 标题:Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones
专利号:WO-2011123947-A1 优先权日:2010-04-06 标 题:Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'- indolin]-2'-ones
专利号:US-2017226088-A1 优先权日:2010-04-06 标 题:Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-ones
专利号:US-2015133677-A1 优先权日:2010-04-06 标题:Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-ones
专利号:US-2018105511-A1 优先权日:2010-04-06 标题:Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-ones
专利号:US-8921545-B2 优先权日:2010-04-06 标 题 :Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones
参考文献:10.1016/j.bmcl.2016.04.073 摘要:Cheruvallath Z, Tang M, McBride C, Komandla M, Miura J, Ton-Nu T, Erikson P, Feng J, Farrell P, Lawson JD, Vanderpool D, Wu Y, Dougan DR, Plonowski A, Holub C, Larson C. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 1. Bioorganic & Medicinal Chemistry Letters. 2016 Jun;26(12):2774–8. doi: 10.1016/j.bmcl.2016.04.073.